A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol

Peer Review reports

Original Submission
31 May 2021	Submitted	Original manuscript
8 Aug 2021	Reviewed	Reviewer Report - Riaz Qureshi
8 Sep 2021	Author responded	Author comments - I García-García
Resubmission - Version 2
8 Sep 2021	Submitted	Manuscript version 2
Publishing
14 Sep 2021	Editorially accepted
2 Oct 2021	Article published	10.1186/s13063-021-05625-7

Back to article page